You are here

Siena Biotech’s failure: consequences on HD research

×

Error message

Notice: Undefined index: disabled_javascripts in eu_cookie_compliance_page_build() (line 306 of /home/ferdsq/domains/lirh.it/public_html/sites/all/modules/eu_cookie_compliance/eu_cookie_compliance.module).
 

Siena Biotech was born in 2000 with the aim to discover drugs for neurodegenerative and rare diseases, like Huntington Disease.

In the last weeks, many articles have been published on Siena Biotech failure,  stating that HD research will be stopped on a promosing drug. 

Siena Biotech produced a molecule, called Selisistat, that started to be tested on HD patients.

 

PHASE I AND II – WHAT COMES TO LIGHT

Selisistat was tested in Phase I (to verify its tolerability on humans, after having been tested on laboratory animals) and in Phase II (to verify therapeutic effectiveness on few people).
At this point, it didn’t produce relevant results on medical case and it showed a decent safety.
This means that  - in order to verify if the molecle is more efficient than the drugs already in market and to see the relationship between risks and benefits for patients - it is absolutely necessary a Phase III, where the drug will be given to hundreds of patients.

 

PHASE III - MISSING

Siena Biotech’s wind up by the MPS Foundation stopped molecule testing in phase III.
So, up to now, we don’t know if Selisistat can be or not an useful drug for HD patients and we won’t know, without a phase III study.

 

We hope that Siena Biotech will exit from the crisis but our message to HD people is that many other promising therapies for Huntington are waiting for scientific experimental validation.

 
AttachmentSize
PDF icon La Stampa, 25.02.2015822.69 KB
 
 

Codice Fiscale 90026220948 -  P. Iva 00907370944
Iscrizione al n.88 del Registro delle Persone Guridiche della Prefettura di Isernia.

Copyright © 2017 Fondazione Lega Italiana Ricerca Huntington